ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010
Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 69 citations in OpenAlex.
- Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.The American journal of psychiatry · 2018Trial
- A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.British journal of pharmacology · 2012Trial
- Nicotine and neuronal nicotinic acetylcholine receptors: unraveling the mechanisms of nicotine addiction.Frontiers in neuroscience · 2025Review
- Neurobiology of Stress-Induced Nicotine Relapse.International journal of molecular sciences · 2024Review
- The role of beta- and alpha-adrenergic receptors on alcohol drinking.Neuropharmacology · 2023Article
- Development of Dependence in Smokers and Rodents With Voluntary Nicotine Intake: Similarities and Differences.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Review
- Tobacco and nicotine use.Nature reviews. Disease primers · 2022Review
- The role of anterior insula-brainstem projections and alpha-1 noradrenergic receptors for compulsion-like and alcohol-only drinking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects.Psychopharmacology · 2021Article
- Identification ofeLife · 2020Article
- Mechanisms of Shared Vulnerability to Post-traumatic Stress Disorder and Substance Use Disorders.Frontiers in behavioral neuroscience · 2020Review
- Effects of the Alpha-1 Antagonist Prazosin on KOR Agonist-Induced Reinstatement of Alcohol Seeking.The international journal of neuropsychopharmacology · 2019Article
- Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse.Molecular neuropsychiatry · 2019Review
- Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior.Journal of psychopharmacology (Oxford, England) · 2018Article
- Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.Psychopharmacology · 2018Article
- Effect of doxazosin on stress reactivity and the ability to resist smoking.Journal of psychopharmacology (Oxford, England) · 2017Article
- Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.Psychopharmacology · 2016Review
- Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings.Current addiction reports · 2016Article
- Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.Brain research · 2016Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Nicotine is the main psychoactive ingredient in tobacco and its rewarding effects are considered primarily responsible for persistent tobacco smoking and relapse. Although dopamine has been extensively implicated in the rewarding effects of nicotine, noradrenergic systems may have a larger role than previously suspected. This study evaluated the role of noradrenergic alpha(1) receptors in nicotine and food self-administration and relapse, nicotine discrimination, and nicotine-induced dopamine release in the nucleus accumbens in rats. We found that the noradrenergic alpha(1) receptor antagonist prazosin (0.25-1 mg/kg) dose dependently reduced the self-administration of nicotine (0.03 mg/kg), an effect that was maintained over consecutive daily sessions; but did not reduce food self-administration. Prazosin also decreased reinstatement of extinguished nicotine seeking induced by either a nicotine prime (0.15 mg/kg) or nicotine-associated cues, but not food-induced reinstatement of food-seeking, and decreased nicotine-induced (0.15 mg/kg) dopamine release in the nucleus accumbens shell. However, prazosin did not have nicotine-like discriminative effects and did not alter the dose-response curve for nicotine discrimination. These findings suggest that stimulation of noradrenergic alpha(1) receptors is involved in nicotine self-administration and relapse, possibly via facilitation of nicotine-induced activation of the mesolimbic dopaminergic system. The findings point to alpha(1) adrenoceptor blockade as a potential new approach to the treatment of tobacco dependence in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.